BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering

路透社2026/10/06 11:26

Show original

On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

October 6 - ** Spyre Therapeutics (SYRE.O) shares fell 4.1% in premarket trading to $88.90 after the company priced a subsequent $350 million financing

** The biotechnology company announced late Monday (link) that it is offering approximately 4.1 million shares at $85 each, an 8.3% discount to the last closing price

** The company plans to use the net proceeds to advance its projects in gastroenterology, rheumatology, and dermatology, and to move forward with a new project—advancing SPY072 to late-stage development for the chronic skin disease “hidradenitis suppurativa,” among other uses

** Jefferies, TD Cowen, Leerink, and Stifel served as joint bookrunners

** On September 30, Merck (MRK.N)’s drug tulisokibart succeeded in a dermatology clinical trial (link), after which SYRE shares rose roughly 5%; analysts said the data supports SYRE's experimental candidate targeting the same pathway

** SYRE, headquartered in Waltham, Massachusetts, had about 88.2 million shares outstanding before the offering

** As of Monday’s close, the stock has risen 183% year-to-date

** According to LSEG data, out of 17 analysts, 16 give the stock a “strong buy” or “buy” rating, 1 rates it “hold”; the median price target is $123

(To assist non-native English speakers, Reuters automates the translation of its reports into several other languages. Because automated translation may be faulty or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters assumes no liability for any damage or loss caused by the use of automated translation functionality.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Briefing": https://refini.tv/3dKUyB8 Reuters, October 6 - U.S. stock index futures rose on Tuesday as Treasury yields retreated from multi-year highs and oil prices declined, providing a bit of relief for investors ahead of the quarterly earnings season. ** MYR Group MYRG.O: Market Spotlight — Jefferies upgraded MYR Group to "Buy"; stock price rose nL4N45S0PK ** Spyre Therapeutics SYRE.O: Market Action — Spyre Therapeutics shares fell due to a $350 millions stock offering nL6N45S0PG ** AMD.O: Market Action — AMD shares rose on plans to increase chip supply nL4N45S0Q7 ** Constellation Energy CEG.O: Highlight — Alphabet reportedly close to signing a multi-year nuclear energy deal, Constellation Energy shares climbed nL6N45S0HX ** Nike NKE.N: Highlight — Berenberg downgraded Nike to "Sell"; shares declined nL6N45S0KB ** Option Care Health OPCH.O: Highlight — Option Care Health surged after reportedly receiving a buyout offer exceeding $5 billions nL4N45S0L5 ** Freshworks Inc FRSH.O: Market Action — Freshworks stock advanced as it is set to be added to the S&P SmallCap 600 nL4N45S0IT (For the convenience of non-English speakers, Reuters automatically translates its reports into various other languages. As automatic translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters is not responsible for any damage or loss caused by the use of automatic translation features.)

路透社•2026/10/06 11:48

Top Premarket Decliners

07:38 AM EDT, 10/06/2026 (MT Newswires) -- Armada Acquisition Corp. II (XRPN) shares were down more than 16% in premarket activity Tuesday following a nearly 2% fall in the prior session. HeartSciences (HSCS) stock was 14% lower after a 1.4% gain in the prior session. WISeSat.Space (SAIQ) shares were down 13% after a 260% rise at the previous close. CTW (CTW) stock was 7% lower after remaining flat at Monday's close. Republic Power Group (RPGL) shares were down 4% after a regulatory filing showed that the company and its institutional investor mutually agreed to terminate an additional investment right, with Republic paying a $250,000 termination fee.

MT newswire•2026/10/06 11:38